Advertisement

 

 

Novel biomarker SYT12 may contribute to predicting papillary thyroid cancer outcomes.

Novel biomarker SYT12 may contribute to predicting papillary thyroid cancer outcomes.
Author Information (click to view)

Jonklaas J, Murthy S, Liu D, Klubo-Gwiezdzinska J, Krishnan J, Burman KD, Boyle L, Carrol N, Felger E, Loh YP,


Jonklaas J, Murthy S, Liu D, Klubo-Gwiezdzinska J, Krishnan J, Burman KD, Boyle L, Carrol N, Felger E, Loh YP, (click to view)

Jonklaas J, Murthy S, Liu D, Klubo-Gwiezdzinska J, Krishnan J, Burman KD, Boyle L, Carrol N, Felger E, Loh YP,

Advertisement

Future science OA 2017 09 224(1) FSO249 doi 10.4155/fsoa-2017-0087

Abstract
Aim
To investigate biomarkers for predicting papillary thyroid cancer outcomes.

Materials & methods
The expression of biomarkers (ITGA2, SYT12 and CDH3) was studied in a prospective cohort of patients with papillary thyroid cancer. Three outcomes of initial metastases, baseline status and longitudinal status were analyzed and correlated with the biomarkers.

Results
SYT12 provided the best prediction of initial metastasis (sensitivity: 72%; specificity: 54%). SYT12 had the highest accuracy for predicting longitudinal status (sensitivity: 100%; specificity: 47%). The best performance for longitudinal status resulted from combining SYT12 with American Thyroid Association risk stratification, with sensitivity and specificity of 88 and 73%, respectively.

Conclusion
SYT12 has some prognostic significance in papillary thyroid cancer. Further validation studies in larger populations are warranted.

Submit a Comment

Your email address will not be published. Required fields are marked *

four × 1 =

[ HIDE/SHOW ]